tiprankstipranks
Oncimmune Holdings PLC (DE:OCY)
STUTTGART:OCY

Oncimmune Holdings Stock Price & Analysis

0 Followers

OCY Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€0.64
Volume0.00
Average Volume (3M)N/A
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)€2.53M
Total Debt (Recent Filing)€0.00
P/E RatioN/A
Beta1.07
Next EarningsFeb 15, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)N/A
Shares OutstandingN/A
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
P/B RatioN/A
P/S RatioN/A
P/CF RatioN/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
AlphaN/A
Number of Analyst Covering0


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

OCY FAQ

What was Oncimmune Holdings’s price range in the past 12 months?
Currently, no data Available
What is Oncimmune Holdings’s market cap?
Currently, no data Available
When is Oncimmune Holdings’s upcoming earnings report date?
Oncimmune Holdings’s upcoming earnings report date is Feb 15, 2023 which is in 131 days.
    How were Oncimmune Holdings’s earnings last quarter?
    Oncimmune Holdings released its earnings results on Sep 21, 2022. The company reported -€0.077 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.077.
      Is Oncimmune Holdings overvalued?
      According to Wall Street analysts Oncimmune Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Oncimmune Holdings pay dividends?
        Oncimmune Holdings does not currently pay dividends.
        What is Oncimmune Holdings’s EPS estimate?
        Oncimmune Holdings’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Oncimmune Holdings have?
        Currently, no data Available
        What happened to Oncimmune Holdings’s price movement after its last earnings report?
        Oncimmune Holdings reported an EPS of -€0.077 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -23.077%.
          Which hedge fund is a major shareholder of Oncimmune Holdings?
          Currently, no hedge funds are holding shares in DE:OCY

          ---

          Oncimmune Holdings Stock Analysis

          Smart ScoreUnderperform
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10
          1

          Analyst Consensus

          N/A
          Currently Not Enough Data Available

          Blogger Sentiment

          N/A
          Currently Not Enough Data Available

          Insider Transactions

          ▲ Bought Shares
          Worth £5.0K over the Last 3 Months

          News Sentiment

          N/A
          Currently Not Enough Data Available

          Technicals

          SMA
          Negative
          20 days / 200 days
          Momentum
          -67.89%
          12-Months-Change

          Fundamentals

          Return on Equity
          -760.96%
          Trailing 12-Months
          Asset Growth
          -28.92%
          Trailing 12-Months
          The Oncimmune Holdings Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
          Learn more about TipRanks Smart Score

          Company Description

          Oncimmune Holdings PLC

          Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes EarlyCDT and ImmunoINSIGHTS. It generates maximum revenue from the EarlyCDT segment.

          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          4d Pharma
          Scancell Holdings
          Avacta Group plc
          ANGLE plc
          E Therapeutics

          Popular Stocks

          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis